AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$ANIX

KUMAR AMIT purchased $8K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 3,000 shares of Anixa Biosciences Inc (ANIX) at $2.75 on 2026-09-10.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Sep 14, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 1:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Neutral
high confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXNeutralLow
01

Why it matters

The purchase is a routine insider transaction with limited market impact.

02

Market read

Low relevance; the trade size is small and unlikely to affect the stock price.

03

What to watch

Potential future insider activity if more purchases follow.

Relevance 4/10Novelty 4/10Timing: filed Sep 14, 2026

Background

Form 4 disclosures provide the first public record of insider trades.

Company-level read

Ticker impact

$ANIXNeutralHigh confidence
Context

CEO Kumar Amit bought 3,000 shares of Anixa Biosciences for $8,250 in a Form 4 filing.

Expected impact

minimal impact, possible slight positive bias

Evidence & confidence

The transaction size is modest relative to market cap and typical daily volume.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could signal confidence, but size is too small to be meaningful.

Key entities

  • Company
    Anixa Biosciences Inc

    Biotech firm listed on NASDAQ (ANIX).

  • Insider
    Kumar Amit

    Chief Executive Officer of Anixa Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
SEP 17
$XBPLow

Avenue RP Opportunities Fund, L.P. (LASRY MARC) purchased $1.5M of XBP (indirect holdings)

Avenue RP Opportunities Fund, L.P. purchased 527,606 indirectly-held shares of XBP Global Holdings, Inc. (XBP) at $2.83 ($1.49M total) across 2 trades on 2026-09-15. Filed jointly with Avenue Global Dislocation Opportunities Fund, L.P. (10% owner), Avenue Europe International Management, L.P. (10% owner), Avenue Capital Management II, L.P. (10% owner), Avenue RP Opportunities Fund GenPar, LLC (10% owner), Avenue Global Dislocation Opportunities GenPar, LLC (10% owner), GL RP Partners, LLC (10% owner), GL Global Dislocation Opportunities Partners, LLC (10% owner) and LASRY MARC (10% owner).

SEC EDGAR1 min